加载中
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
前收盘价
US$8.33
+US$0.32 · +4.00%
盘中时间采用ET。市场数据可能有所延迟。
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
日内区间
当前US$8.33
52周区间
当前US$8.33
盘中时间采用ET。市场数据可能有所延迟。
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
日内区间
当前US$8.33
52周区间
当前US$8.33
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 2461.4万 USD | 1905.7万 USD | 1311万 USD | 783.9万 USD | 876.5万 USD |
| 销售、一般及管理费用 | 978.3万 USD | 762.4万 USD | 815.7万 USD | 616.2万 USD | 488.1万 USD |
| 营业费用 | 3439.7万 USD | 2668.1万 USD | 2126.7万 USD | 1400.1万 USD | 1364.6万 USD |
| 利息收入 | — | 230.1万 USD | — | — | — |
| 折旧和摊销 | 4.3万 USD | 3.9万 USD | 3万 USD | 2.5万 USD | 2.4万 USD |
| 营业利润 | −3439.7万 USD | −2668.1万 USD | −2126.7万 USD | −1400.1万 USD | −1364.6万 USD |
| 净利润 | −3276.6万 USD | −2444.4万 USD | −1938.1万 USD | −1367.6万 USD | −1359.2万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM763.97万0.01%787.4亿 USD0.19%US$278.94+0.49%
iShares Russell 2000 Growth ETFIWO274.6万0.02%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF228.95万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO133.27万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC91.94万0.07%13.17亿 USD0.60%US$183+0.11%
Vanguard Russell 2000 Growth ETFVTWG25.73万0.01%17亿 USD0.06%US$260.49+0.91%
Global X - Russell 2000 ETFRSSL14.48万0.01%14.19亿 USD0.08%US$109.09+0.21%
ProShares Russell 2000 High Income ETFITWO1.78万0.01%1.85亿 USD0.55%US$43.06+0.96%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGGlobal X - Russell 2000 ETFRSSLProShares Russell 2000 High Income ETFITWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
